Vermillion (VRML +23.2%) says the U.S. Patent and Trademark Office granted a patent on the use...


Vermillion (VRML +23.2%) says the U.S. Patent and Trademark Office granted a patent on the use of the company's Protein C Inhibitor in tests to measure the presence or progress of ovarian cancer. "The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1," VRML's chief science officer says.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs